Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Tempus AI — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.19 (market cap $1.47B), while Tempus AI trades at $70.22 (market cap $12.77B). The key difference: Tempus AI is far larger — about 8.7× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days and Tempus AI for 22 Days on average.
| QQQE | TEM | |
|---|---|---|
Market Cap | $1.47B | $12.77B |
Volume | 181,648 | 8,980,490 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $124.69 | $99.28 |
52-Week Low | $96.06 | $41.55 |
Typical Hold Time | 47 Days | 22 Days |
Enterprise Value | — | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.89, down 0.89% on the day. The ETF maintains a bullish technical outlook with strong moving average signals while oscillators show neutral momentum. Recent analysis highlights QQQE's advantage over traditional NASDAQ-100 ETFs due to its equal-weight approach, reducing technology concentration from 60% to 45% while maintaining exposure to large-cap growth stocks.
The equal-weight methodology provides diversification benefits amid tech sector volatility. Key risks include market concentration in growth stocks and broader market sentiment shifts. Recent analyst commentary suggests tactical opportunities in equal-weight strategies for the coming year, though investors should monitor sector rotation trends.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
